**Traders see little near-term risk of a new COVID variant of concern before 2027, pricing “No” at 92.5%.** Current global surveillance shows no SARS-CoV-2 lineages meeting WHO or ECDC VOC criteria, with only variants under monitoring such as PQ.16.1.1 under review as of late July 2026. The most notable recent lineage, BA.3.2, spread modestly in parts of Europe but remained at low U.S. prevalence (around 0.19% through early 2026) and has not produced the combination of markedly higher transmissibility, severity, or immune escape needed for VOC status. Dominant circulating strains remain Omicron sublineages such as XFG.1.1, reflecting gradual evolution rather than abrupt shifts. With only five months left in the period and no signs of rapid escalation in genomic or epidemiological data, the market consensus reflects the limited window and historical pattern of infrequent VOC designations in the endemic phase.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · ОбновленоДа
$243,750 Объем
$243,750 Объем
Да
$243,750 Объем
$243,750 Объем
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Открытие рынка: Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...**Traders see little near-term risk of a new COVID variant of concern before 2027, pricing “No” at 92.5%.** Current global surveillance shows no SARS-CoV-2 lineages meeting WHO or ECDC VOC criteria, with only variants under monitoring such as PQ.16.1.1 under review as of late July 2026. The most notable recent lineage, BA.3.2, spread modestly in parts of Europe but remained at low U.S. prevalence (around 0.19% through early 2026) and has not produced the combination of markedly higher transmissibility, severity, or immune escape needed for VOC status. Dominant circulating strains remain Omicron sublineages such as XFG.1.1, reflecting gradual evolution rather than abrupt shifts. With only five months left in the period and no signs of rapid escalation in genomic or epidemiological data, the market consensus reflects the limited window and historical pattern of infrequent VOC designations in the endemic phase.
Экспериментальная сводка, созданная ИИ на основе данных Polymarket. Это не является торговой рекомендацией и не влияет на то, как разрешается этот рынок. · Обновлено
Не доверяй внешним ссылкам.
Не доверяй внешним ссылкам.
Часто задаваемые вопросы